41.68 USD
+0.82 (+2.01%)
At close: Jan 30, 2026
41.68 USD
0 (0%)
After Hours: 1/30/2026, 8:17:24 PM
We assign a fundamental rating of 6 out of 10 to RPRX. RPRX was compared to 190 industry peers in the Pharmaceuticals industry. RPRX scores excellent on profitability, but there are some minor concerns on its financial health. RPRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
- RPRX had positive earnings in the past year.
- In the past year RPRX had a positive cash flow from operations.
- RPRX had positive earnings in each of the past 5 years.
- RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- RPRX's Return On Assets of 3.95% is amongst the best of the industry. RPRX outperforms 84.74% of its industry peers.
- The Return On Equity of RPRX (11.93%) is better than 86.32% of its industry peers.
- RPRX's Return On Invested Capital of 6.43% is amongst the best of the industry. RPRX outperforms 84.21% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.83%.
- The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
- The Profit Margin of RPRX (32.55%) is better than 95.26% of its industry peers.
- RPRX's Profit Margin has declined in the last couple of years.
- The Operating Margin of RPRX (65.22%) is better than 100.00% of its industry peers.
- In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- RPRX has less shares outstanding than it did 1 year ago.
- RPRX has more shares outstanding than it did 5 years ago.
- RPRX has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.73, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
- RPRX has a Altman-Z score of 1.73. This is comparable to the rest of the industry: RPRX outperforms 58.42% of its industry peers.
- RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
- RPRX's Debt to FCF ratio of 9.47 is fine compared to the rest of the industry. RPRX outperforms 79.47% of its industry peers.
- A Debt/Equity ratio of 1.34 is on the high side and indicates that RPRX has dependencies on debt financing.
- RPRX has a worse Debt to Equity ratio (1.34) than 75.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.73 |
ROIC/WACC0.75
WACC8.62%
2.3 Liquidity
- RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 55.79% of the companies in the same industry.
- RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX has a Quick ratio (3.48) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
- RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
- The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
- Looking at the last year, RPRX shows a small growth in Revenue. The Revenue has grown by 3.70% in the last year.
- Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 4.52% on average per year.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
- The Earnings Per Share is expected to grow by 10.53% on average over the next years. This is quite good.
- Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 10.65% on average per year.
EPS Next Y17.31%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue Next Year17.2%
Revenue Next 2Y9.47%
Revenue Next 3Y8.62%
Revenue Next 5Y10.65%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- RPRX is valuated reasonably with a Price/Earnings ratio of 10.14.
- Compared to the rest of the industry, the Price/Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 91.05% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of RPRX to the average of the S&P500 Index (28.30), we can say RPRX is valued rather cheaply.
- RPRX is valuated reasonably with a Price/Forward Earnings ratio of 8.03.
- 91.58% of the companies in the same industry are more expensive than RPRX, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.57, RPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.14 | ||
| Fwd PE | 8.03 |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 83.16% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.47 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of RPRX may justify a higher PE ratio.
- A more expensive valuation may be justified as RPRX's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y12.49%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
- RPRX has a Yearly Dividend Yield of 2.34%.
- RPRX's Dividend Yield is rather good when compared to the industry average which is at 0.48. RPRX pays more dividend than 93.16% of the companies in the same industry.
- RPRX's Dividend Yield is a higher than the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.34% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.14 and the Price/Book (PB) ratio is 3.75.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 5 / 10 and the dividend payout ratio is 49.36%.